JP2019505564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505564A5 JP2019505564A5 JP2018544769A JP2018544769A JP2019505564A5 JP 2019505564 A5 JP2019505564 A5 JP 2019505564A5 JP 2018544769 A JP2018544769 A JP 2018544769A JP 2018544769 A JP2018544769 A JP 2018544769A JP 2019505564 A5 JP2019505564 A5 JP 2019505564A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- host cell
- binding moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012636 effector Substances 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 101100029145 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PE25 gene Proteins 0.000 claims 1
- -1 PE24 Proteins 0.000 claims 1
- 101150112800 PE35 gene Proteins 0.000 claims 1
- 101150030083 PE38 gene Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000011748 cell maturation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255255P | 2015-11-13 | 2015-11-13 | |
| US62/255,255 | 2015-11-13 | ||
| US201562257493P | 2015-11-19 | 2015-11-19 | |
| US62/257,493 | 2015-11-19 | ||
| PCT/US2016/061320 WO2017083511A1 (en) | 2015-11-13 | 2016-11-10 | Anti-bcma polypeptides and proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505564A JP2019505564A (ja) | 2019-02-28 |
| JP2019505564A5 true JP2019505564A5 (OSRAM) | 2019-12-19 |
| JP6901493B2 JP6901493B2 (ja) | 2021-07-14 |
Family
ID=57354453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544769A Active JP6901493B2 (ja) | 2015-11-13 | 2016-11-10 | 抗ｂｃｍａポリペプチド及びタンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10925969B2 (OSRAM) |
| EP (1) | EP3374396A1 (OSRAM) |
| JP (1) | JP6901493B2 (OSRAM) |
| KR (1) | KR102776145B1 (OSRAM) |
| CN (1) | CN108473575B (OSRAM) |
| AU (1) | AU2016353067B2 (OSRAM) |
| CA (1) | CA3005042A1 (OSRAM) |
| WO (1) | WO2017083511A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102086874B1 (ko) | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| MX387517B (es) | 2015-04-06 | 2025-03-18 | Subdomain Llc | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
| HK1259075A1 (zh) | 2016-02-17 | 2019-11-22 | Seattle Genetics, Inc. | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| JP7356354B2 (ja) | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用 |
| CA3082410A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
| EA202091198A1 (ru) * | 2017-11-14 | 2020-09-09 | Эрселлкс, Инк. | Полипептиды, содержащие домен d, и их применение |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| CA3081125C (en) | 2018-02-01 | 2025-09-16 | Innovent Biologics (Suzhou) Co., Ltd. | All-Human Single-Chain Variable Fragment Anti-Antigen for B Lymphocyte Maturation (BCMA), and Associated Application |
| BR112020017053A2 (pt) * | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| SG11202011080QA (en) | 2018-05-11 | 2020-12-30 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| WO2020004937A1 (ko) * | 2018-06-26 | 2020-01-02 | 주식회사 티에스디라이프사이언스 | 항-bcma 항체-약물 접합체 및 그 용도 |
| PT3823665T (pt) | 2018-07-19 | 2024-02-26 | Regeneron Pharma | Recetores antigénicos quiméricos que possuem uma especificidade para o bcma e utilizações dos mesmos |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| TW202028239A (zh) * | 2018-09-28 | 2020-08-01 | 美商安進公司 | 針對可溶性bcma之抗體 |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| WO2020073215A1 (zh) * | 2018-10-10 | 2020-04-16 | 深圳华大生命科学研究院 | 抗BCMA单链抗体scFv及其制备方法和应用 |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| JP2022531185A (ja) | 2019-04-30 | 2022-07-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法 |
| CA3146394A1 (en) * | 2019-07-30 | 2021-02-04 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| WO2021190564A1 (zh) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| WO2024051796A1 (en) * | 2022-09-09 | 2024-03-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Albumin binding proteins, fusion proteins and uses thereof |
| CN117164714B (zh) * | 2023-10-08 | 2024-04-23 | 北京奇迈永华生物科技有限公司 | 一种靶向bcma的抗体及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| DE69131449T2 (de) | 1990-05-11 | 1999-11-25 | The United States Of America, Represented By The Secretary | Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| DE69333951D1 (de) | 1992-06-18 | 2006-02-02 | Us Gov Health & Human Serv | Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität |
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| EP1910407B1 (en) | 2005-07-29 | 2011-09-14 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
| US8871906B2 (en) | 2007-09-04 | 2014-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| NZ594985A (en) * | 2009-03-10 | 2013-07-26 | Biogen Idec Inc | Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies |
| RU2012114005A (ru) | 2009-09-11 | 2013-10-20 | Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез | Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью |
| EP2488200A4 (en) * | 2009-10-14 | 2013-06-12 | Merck Sharp & Dohme | APRIL ANTAGONISTS AND METHOD FOR THEIR USE |
| PE20141045A1 (es) * | 2011-05-27 | 2014-09-10 | Glaxo Group Ltd | Proteinas de union a bcma (cd269/tnfrsf17) |
| WO2012170617A1 (en) | 2011-06-09 | 2012-12-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes |
| HK1198170A1 (en) | 2011-09-16 | 2015-03-13 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| KR102086874B1 (ko) * | 2012-04-11 | 2020-03-10 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
| JP6694712B2 (ja) | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9388222B2 (en) | 2013-10-06 | 2016-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified Pseudomonas exotoxin A |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
-
2016
- 2016-11-10 US US15/773,687 patent/US10925969B2/en active Active
- 2016-11-10 KR KR1020187016668A patent/KR102776145B1/ko active Active
- 2016-11-10 EP EP16798612.4A patent/EP3374396A1/en not_active Ceased
- 2016-11-10 JP JP2018544769A patent/JP6901493B2/ja active Active
- 2016-11-10 WO PCT/US2016/061320 patent/WO2017083511A1/en not_active Ceased
- 2016-11-10 AU AU2016353067A patent/AU2016353067B2/en active Active
- 2016-11-10 CN CN201680065438.5A patent/CN108473575B/zh active Active
- 2016-11-10 CA CA3005042A patent/CA3005042A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505564A5 (OSRAM) | ||
| JP2016500655A5 (OSRAM) | ||
| JP2020501531A5 (OSRAM) | ||
| JP2022512132A (ja) | 抗クローディン抗体及びそれらの使用 | |
| JP2015510761A5 (OSRAM) | ||
| JP2017531427A5 (OSRAM) | ||
| JP2010511388A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| JP2011505875A5 (OSRAM) | ||
| JP2016138129A5 (OSRAM) | ||
| JP2010510809A5 (OSRAM) | ||
| JP2015526387A5 (OSRAM) | ||
| JP2017526339A5 (OSRAM) | ||
| Stone et al. | The assembly of single domain antibodies into bispecific decavalent molecules | |
| JP2016533721A5 (OSRAM) | ||
| JP2012523848A5 (OSRAM) | ||
| JP2003523771A5 (OSRAM) | ||
| JP2010533498A5 (OSRAM) | ||
| JP2016536342A5 (OSRAM) | ||
| CN110831973A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2013519364A5 (OSRAM) | ||
| JP2012519492A5 (OSRAM) | ||
| JP2019512207A5 (OSRAM) | ||
| JP2020533004A5 (OSRAM) | ||
| JP2018530331A5 (OSRAM) |